Study S000355

A Proof-of-Concept, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of Oral NG101 in the Treatment of Side Effects in Healthy Adult Participants Administered a Single Subcutaneous Dose of a Glucagon-Like Peptide 1 Agonist

ClinicalTrials.gov record

Registration

Registration: NCT06500429
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 120
Start: 2024-06-24
Primary completion: 2024-09-04
Lead sponsor: Neurogastrx, Inc.
Conditions: Overweight and Obesity; Healthy
Interventions: DRUG:NG101; DRUG:Placebo; DRUG:Semaglutide Injectable Product
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Duration of GI-related adverse events [96 hours following GLP-1 agonist injection]
Severity of GI-related adverse events [96 hours following GLP-1 agonist injection]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.